Stock PDSB PDS BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Real-time Estimate Cboe BZX
Other stock markets
 20:03:27 01/05/2024 BST 		5-day change 1st Jan Change
3.755 USD +12.09% Intraday chart for PDS Biotechnology Corporation +13.54% -25.75%
03-28 B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating MT
03-27 Empire Metals targets key milestones in Australia AN

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Empire Metals targets key milestones in Australia
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
PDS Biotechnology Corporation Announces Publication of Preclinical Research
PDS Biotechnology Corporation Announces Executive Changes
Apyx Medical Names Matthew Hill as CFO
PDS Biotechnology Appoints Lars Boesgaard as Finance Chief
PDS Biotechnology Corporation Announces Resignation of Matthew Hill as Principal Financial Officer and Principal Accounting Officer, Effective December 1, 2023
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
NetScientific's portfolio company updates on cancer trial
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients
NetScientific investee claims promising results in biomarker study
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
NetScientific portfolio company updates on cancer trial
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA
PDS Biotechnology Investigational Vaccine Shows 'Active Neutralization' of Multiple Influenza Viruses in Preclinical Studies
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
NetScientific's PDS suffers wider loss as R&D costs mount
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. News PDS Biotechnology Corporation
  5. Other languages